Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 687, doi. 10.1007/s40259-022-00562-6
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2022 AND VI 36 AND IP 6
Results: 10
1
2
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 673, doi. 10.1007/s40259-022-00561-7
- By:
- Publication type:
- Article
3
Correction: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
4
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 731, doi. 10.1007/s40259-022-00559-1
- By:
- Publication type:
- Article
5
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 781, doi. 10.1007/s40259-022-00558-2
- By:
- Publication type:
- Article
6
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 773, doi. 10.1007/s40259-022-00557-3
- By:
- Publication type:
- Article
7
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 717, doi. 10.1007/s40259-022-00556-4
- By:
- Publication type:
- Article
8
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 701, doi. 10.1007/s40259-022-00555-5
- By:
- Publication type:
- Article
9
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog<sup>®</sup>) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 761, doi. 10.1007/s40259-022-00554-6
- By:
- Publication type:
- Article
10
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
- Published in:
- BioDrugs, 2022, v. 36, n. 6, p. 749, doi. 10.1007/s40259-022-00552-8
- By:
- Publication type:
- Article